(0.33%) 5 117.03 points
(0.33%) 38 365 points
(0.37%) 15 987 points
(-0.98%) $83.03
(5.56%) $2.03
(0.34%) $2 355.20
(0.48%) $27.67
(4.05%) $959.45
(-0.26%) $0.932
(-0.41%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia...
Stats | |
---|---|
本日の出来高 | 23 612.00 |
平均出来高 | 32 383.00 |
時価総額 | 7.33M |
EPS | $0 ( 2024-04-02 ) |
次の収益日 | ( $-2.20 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.250 |
ATR14 | $0.0410 (1.41%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | King Thomas Braxton | Buy | 3 110 | Restricted stock units |
2024-04-18 | Patane Michael A | Buy | 3 556 | Restricted stock units |
2024-04-18 | Lee Catherine Chai-zon | Buy | 3 556 | Restricted stock units |
2024-04-18 | Mills Robert S | Buy | 4 667 | Restricted stock units |
2024-04-18 | Roberts Brandi | Buy | 5 333 | Restricted stock units |
INSIDER POWER |
---|
71.14 |
Last 95 transactions |
Buy: 4 806 950 | Sell: 2 066 322 |
TFF Pharmaceuticals Inc 相関
10 最も正の相関 | |
---|---|
MRACW | 0.954 |
BIOL | 0.949 |
NRBO | 0.946 |
RMRM | 0.942 |
KBSF | 0.94 |
SLNH | 0.939 |
GRNV | 0.935 |
AVCT | 0.934 |
AYLA | 0.929 |
TDAC | 0.927 |
10 最も負の相関 | |
---|---|
VLYPO | -0.938 |
BOCH | -0.931 |
IART | -0.923 |
SLGN | -0.92 |
MMAC | -0.919 |
RFEU | -0.919 |
LMRK | -0.918 |
INNV | -0.917 |
LOPE | -0.914 |
AGFS | -0.911 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
TFF Pharmaceuticals Inc 財務諸表
Annual | 2023 |
収益: | $733 871 |
総利益: | $231 391 (31.53 %) |
EPS: | $-11.85 |
FY | 2023 |
収益: | $733 871 |
総利益: | $231 391 (31.53 %) |
EPS: | $-11.85 |
FY | 2022 |
収益: | $0 |
総利益: | $-388 221 (0.00 %) |
EPS: | $-26.49 |
FY | 2021 |
収益: | $88.00 |
総利益: | $88.16 (100.00 %) |
EPS: | $-0.00152 |
Financial Reports:
No articles found.
TFF Pharmaceuticals Inc
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。